B. Gordon et al., Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients, BONE MAR TR, 25(1), 2000, pp. 79-83
Citations number
25
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Development of CNS dysfunction in the setting of hematopoietic stem cell tr
ansplant (HSCT) has been previously shown to predict for subsequent second
organ dysfunction and death. In this paper, we describe the characteristics
of this isolated CNS dysfunction, and its relationship to multiple organ d
ysfunction syndrome (MODS) after HSCT, Twenty-one of 186 patients undergoin
g HSCT developed CNS dysfunction as their first organ dysfunction a mean of
22.8 +/- 0.9 days after the start of the preparative regimen. Compared wit
h 137 patients who developed no organ dysfunction, patients presenting with
CNS dysfunction were more likely to have undergone allogeneic HSCT (P = 0.
001) and to have received a total body irradiation-based regimen (P = 0.001
), and were less likely to have been transplanted for lymphoma (P = 0.008).
Patients who developed CNS dysfunction were more likely to die than those
with no organ dysfunction (P < 0.001). Of the 21 patients who developed CNS
dysfunction, 48% resolved their dysfunction by a mean of 4.6 days later wi
thout progression to second organ dysfunction, and 90% of these patients su
rvived to day 100, Fifty-two percent of patients with CNS dysfunction progr
essed to second organ dysfunction (pulmonary or hepatic) a mean of 5.5 days
later, and only 36% survived to day 100 (P = 0.02). The patients who progr
essed to second organ dysfunction and those who did not were not different
in terms of type of HSCT (allogeneic vs autologous), stem cell source (bloo
d vs bane marrow), age, diagnosis or preparative regimen. Development of CN
S dysfunction in the setting of HSCT, as with other organ dysfunctions (suc
h as hepatic veno-occlusive disease), probably represents an early manifest
ation of a systemic disorder predisposing for MODS, increasing the risk of
transplant-related mortality. Early systemic therapies directed at modulati
ng this systemic disorder are probably indicated.